Missing: Cardiac Power's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cardiac Power's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Cardiac Power News
Aug 12, 2016
Verify here. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: email@example.com. All rights reserved. All other trademarks recognized. Copyright © 1997-2016 BioPortfolio Limited. Site developed by Alacrify Ltd .
Cardiac Power Frequently Asked Questions (FAQ)
Where is Cardiac Power's headquarters?
Cardiac Power's headquarters is located at Cincinnati.
What is Cardiac Power's latest funding round?
Cardiac Power's latest funding round is Series A.
How much did Cardiac Power raise?
Cardiac Power raised a total of $600K.
Who are the investors of Cardiac Power?
Investors of Cardiac Power include Queen City Angels, Blue Chip Venture Company, Health Foundation of Greater Cincinnati and BIOSTART.
Who are Cardiac Power's competitors?
Competitors of Cardiac Power include NeoChord, Angel Medical Systems, Ancora Heart, Respicardia, CardioKinetix and 16 more.
Compare Cardiac Power to Competitors
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.
Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.